Research & Development
Fragment of C. diff toxin shows preclinical promise as breast cancer treatment
A fragment of a
toxin could improve outcomes in patients with hard-to-treat forms of breast cancer, according to a paper published in
November 13, 2023
Genomic Health to pay $32.5M to settle False Claims Act allegations
Genomic Health, a subsidiary of Exact Sciences, has agreed to pay $32.5 million to settle allegations by the U.S. Department of Justice that it violated the False Claims Act by engaging in a scheme to improperly bill Medicare for laboratory tests.
October 4, 2023
Consumer genetic testing may misrepresent breast cancer risk: Study
Women are being told they are at high risk of breast cancer from consumer genetic test results which do not take family history into account, say researchers.
September 21, 2023
Myriad Genetics, Memorial Sloan Kettering collaborate on MRD testing for breast cancer
Myriad Genetics is collaborating with Memorial Sloan Kettering Cancer Center to study the use of Myriad's minimal residual disease testing platform in predicting breast cancer treatment response.
September 18, 2023
Ibex Medical Analytics launches AI-powered breast cancer biomarker scoring platform
Ibex Medical Analytics has launched a breast cancer biomarker scoring tool powered by artificial intelligence (AI) to help clinicians with treatment decisions.
September 11, 2023
NeoGenomics secures Medicare coverage for breast cancer blood test
In the first quarter, NeoGenomics made the RaDaR test fully available to U.S. clinicians, having previously provided it for use in clinical research studies and pharmaceutical collaboration, and completed a filing to MolDx.
August 8, 2023
AccuStem Sciences and EmeritusDX team up on breast cancer assay, product portfolio
Initially, the partnership will focus on furthering the validation of StemPrintER, AccuStem’s recurrence predictor assay for patients with breast cancer.
July 19, 2023
Epigenetic study links DNA methylation to diseases including breast cancer and diabetes
Through the analysis, the researchers identified 69 associations between CpGs and the prevalence of breast cancer, chronic kidney disease, ischemic heart disease, and type 2 diabetes. The majority of the associations had not previously been described.
July 12, 2023
Reveal Genomics highlights results for breast cancer predictive test in phase II clinical trial
Precision oncology firm Reveal Genomics announced that its HER2Dx genomic test for HER2+ breast cancer has been validated in the PHERGain phase II clinical trial.
June 15, 2023
Paige launches AI-based product suite for breast cancer diagnosis
The Paige Breast Suite comprises a group of AI tools designed to support each step of breast cancer diagnosis and streamline pathologists’ day-to-day workflows.
June 15, 2023
CAP, ASCO reduce confusion by reaffirming HER2 testing guidelines
The organizations reaffirmed the Human Epidermal Growth Factor Receptor 2 (HER2) Breast Cancer Testing Guidelines, reducing confusion over terminology for reporting HER2 results.
June 8, 2023
Burning Rock Biotech highlights breast cancer study using its genomic profiling test
In the study, OncoScreen Plus was used to determine activating mutations in PIK3CA and AKT1 and inactivating alterations in PTEN genes for patients in the trial who were enrolled in China.
June 8, 2023
Page 1 of 12